The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.

Slides:



Advertisements
Similar presentations
Remedy Statistics April 2009 May 28th 2009 Paris Desktop Support Analysis only done with Remedy tickets (Incident-Task-Request) (GRS requests are not included.
Advertisements

Longevity & Mortality Risk Transfer via the Capital Markets Guy Coughlan, Managing Director PENSION ADVISORY GROUP S T R I C T L Y P R I V A T E A N D.
Silver linings in dark clouds James McCann RBS Group Economics May 2013.
1 Private & Confidential Real Estate Overview. 2 Private & Confidential Content 2 current projects.
© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Pension Fund Trustees Liability Ncedi Mbongwe. Introduction to Camargue Underwriting Managers Established in 2001 Underwriters: Mutual and Federal and.
Futuro Forum | Bowral 2012 Realm Investment – Fixed Interest.
Irish recovery? Pär Magnusson
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
Saxo Bank OUTLOOK 2011 Saxo Bank’s HQ in Copenhagen June 24, 2015.
Mercer’s Climate Change Research 2011 to 2015
Martin Arnold Director - Research Analyst ETF Securities.
STRICTLY CONFIDENTIAL Positioning for Growth Tasmanian Strata Industry Tim MacKenzie Associate Director Friday 9 th August.
QBE European Operations The QBE Foundation: Giving something back.
HSBC Bank International
An Equity Perspective Paul Malan Global Markets 21 January 2004.
Mike Zenker Barclays Capital Research (415) November 12, 2007
Client Update September 2013 Andrew Tasker – GFM Representative WA.
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2014 by Standard.
Dunedin Enterprise Investment Trust PLC General Meeting – October 2013, Voting Analysis.
Economic & Market Recap May Equity and Fixed Income Markets.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
MacLean Finance Pty Ltd Australia CONFIDENTIALITY DISCLAIMER: The Presenter is not a United States Securities Dealer or Broker, or U.S. Investment Adviser.
Legal Disclaimers Accuracy Every effort is made to provide information that is accurate. However any information contained in this website or the “article.
Place Client Logo Here Oil Market Outlook Paul Horsnell Head of Commodities Research, Barclays Capital Intertanko Singapore Tanker Event 30 March 2006.
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
2009 Coal Seam Gas Safety Forum Paul Zealand, Executive General Manager Upstream Oil & Gas Friday 14 August 2009.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Economic Outlook: relapse or recovery? David Fenton, RBS Group Economics.
RBS, Consumers and the FCA: The economic context and what we’re doing about it Sebastian Burnside, March 2015.
Investec Asset Management Update on Asset Class Returns December 2015.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
FY 2006 results presentation X5 Retail Group N.V. March 1, 2007.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
London CLT Big Potential Presentation 17 th March 2016.
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2011 Standard.
Can Newspapers Survive Paul Harris / London / October 2012.
October 2012 Admission of professional participants – non-credit institutions to trading on the Moscow Exchange FX market.
To us there are no foreign markets. ™ Understanding Your Employee Stock Option Plan June 2014 To us there are no foreign markets. ™
1 The Power of Dividend Growth DISCLOSURE This information has been provided by RBC Global Asset Management Inc. (RBC GAM) and is for informational.
Connectivity to bank and sample account structure
RaboDirect Financial Health Barometer 2016
Risks to the India Sugar Balance Sheet
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Selecting the right provider
Mark Bennett, Head of Agribusiness, ANZ
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Self-Registration walk-through
Presentation Title Sector First Last, Senior Analyst
24 נובמבר 18 סוגיות מס עדכניות ואופיניות לקבוצת חברות בתחום הנדל"ן שאול בן אמוץ, שותף, ראש תחום נדל"ן,PwC Israel יוני, 2016.
Pamplona Credit Opportunities Fund
Open-Source Green Data
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Market linked debentures
Cambria Armor Dividend Strategy Cambria Armor Growth Strategy
Environmental Upgrade Finance
Motivation for 36OU Open Rack
日本株 リアルタイム株価の申込方法.
TITLE PRESENTATIONDATE AUTHOR JOBTITLE.
TITLE Source: Footnotes:. TITLE Source: Footnotes:
© 2013 Sri U-Thong Limited. All rights reserved
AUTHOR JOBTITLE PRESENTATIONDATE
Presentation transcript:

The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only. This is easily resolved by amending the compatibility settings. You may need to speak to your local IT team to implement these changes. MARCH 2016 Secure site compatibility instructions Follow these instructions when the secure site navigation does not function. LGIM secure site compatibility instructions. Alternatively, you could try the compatibility mode icon which should rectify the situation immediately if successful so that you can access the full menu. lf the above solutions do not resolve the issue please let us know. This issue should not occur in any other browser.

MARCH 2016Secure site compatibility instructions Disclaimer and important legal notice Legal & General Investment Management does not provide advice on the suitability of its products or services. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. This presentation, and any information it contains, has been produced for use by professional investor and their advisors only. It should not be distributed without the permission of Legal & General Investment Management Limited. The risks associated with each Fund are set out in the relevant Fund Prospectus and these should be read and understood before making any investment decisions. A copy of the relevant Fund Prospectus can be obtained from your Client Relationship Manager. Legal & General Investment Management has been appointed as a distributor of the funds and to carry out the investment management of the Funds, except for the Property Funds. Confidentiality and Limitations: The information contained in this document (the “Information”) has been prepared by Legal & General Investment Management Limited (“LGIM”, “we” or “us”). Such Information is the propriety and/or confidential information of LGIM and may not be disclosed by you to any other person without the prior written consent of LGIM. Unless otherwise agreed by LGIM in writing, the Information in this document (a) is for information purposes only and we are not soliciting any action based on it, and (b) is not a recommendation to buy or sell securities or pursue a particular investment strategy; and (c) is not investment, legal, regulatory or tax advice. Any trading or investment decisions taken by you should be based on your own analysis and judgment (and/or that of your professional advisors) and not in reliance on us or the Information. To the fullest extent permitted by law, we exclude all representations, warranties, conditions, undertakings and all other terms of any kind, implied by statute or common law, with respect to the Information including (without limitation) any representations as to the quality, suitability, accuracy or completeness of the Information. Any projections, estimates or forecasts included in the Information (a) shall not constitute a guarantee of future events, (b) may not consider or reflect all possible future events or conditions relevant to you (for example, market disruption events); and (c) may be based on assumptions or simplifications that may not be relevant to you. The Information is provided “as is” and “as available”. To the fullest extent permitted by law, LGIM accepts no liability to you or any other recipient of the Information for any loss, damage or cost arising from, or in connection with, any use or reliance on the Information. Without limiting the generality of the foregoing, LGIM does not accept any liability for any indirect, special or consequential loss howsoever caused and on any theory or liability, whether in contract or tort (including negligence) or otherwise, even if Legal & General has been advised or the possibility of such loss. Third Party Data: Where this document contains third party data (“Third Party Data”), we cannot guarantee the accuracy, completeness or reliability of such Third Party Data and accept no responsibility or liability whatsoever in respect such Third Party Data. Publication, amendments and updates: We are under no obligation to update or amend the Information or correct any errors in the Information following the date it was delivered to you. LGIM reserves the right to update this document and/or the Information at any time and without notice. Although the Information contained in this document is believed to be correct as at the time of printing or publication, no assurance can be given to you that this document is complete or accurate in the light of information that may become available after its publication. The Information may not take into account any relevant events, facts or conditions that have occurred after the publication or printing of this document. Issued by Legal & General Investment Management Limited which is authorised and regulated by the Financial Conduct Authority. Legal & General Investment Management, One Coleman Street, London EC2R 5AA Each Fund is a unit linked life fund provided by Legal and General Assurance (Pensions Management) Limited, please refer to the Key Features Document and the Description of Funds document for full details of each Fund's objective, key risks and features